tucatinib; irbinitinib (Tukysa)
Jump to navigation
Jump to search
Indications
* indicated in combination with trastuzumab & capecitabin[2]
Dosage
Tablets: 50 & 150 mg
Pharmacokinetics
- crosses blood brain barrier
Adverse effects
> 20%
- diarrhea
- palmar-plantar erythrodysesthesia
- nausea/vomiting
- fatigue
- hepatotoxicity
- stomatitis
- abdominal pain
- headache
- anemia
- rash
Mechanism of action
- oral tyrosine kinase inhibitor, targets only HER2
More general terms
References
- ↑ MedPage Today Staff. Feb 3, 2020 HER2 Breast Cancer Treatment Effective on Brain Metastases - Patients with brain metastases have historically been excluded from most clinical trials. https://www.medpagetoday.com/meetingcoverage/sabcsvideopearls/84671
- ↑ 2.0 2.1 HIGHLIGHTS OF PRESCRIBING INFORMATION Tukysa* (tucatinib) tablets, for oral use https://seagendocs.com/TUKYSA_Full_Ltr_Master.pdf
- ↑ Medscape: tucatinib (Rx) https://reference.medscape.com/drug/tukysa-tucatinib-4000071